211 related articles for article (PubMed ID: 2164863)
1. Pharmacological properties of FPL 63547, a novel inhibitor of angiotensin-converting enzyme.
Carr RD; Higgs L; Killingback PG; Nicol AK; O'Connor SE; Robson A; Wells E; Simpson WT
Br J Pharmacol; 1990 May; 100(1):83-9. PubMed ID: 2164863
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-converting enzyme inhibition, anti-hypertensive activity and hemodynamic profile of trandolapril (RU 44570).
Brown NL; Badel MY; Benzoni F; Zanirato J; Vincent JC; Fichelle J; Worcel M
Eur J Pharmacol; 1988 Mar; 148(1):79-91. PubMed ID: 3383998
[TBL] [Abstract][Full Text] [Related]
3. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril.
Edling O; Bao G; Feelisch M; Unger T; Gohlke P
J Pharmacol Exp Ther; 1995 Nov; 275(2):854-63. PubMed ID: 7473177
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride.
Friehe H; Ney P
Arzneimittelforschung; 1997 Feb; 47(2):132-44. PubMed ID: 9079232
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive action of a novel orally active angiotensin converting enzyme inhibitor altiopril calcium (MC-838) in several hypertensive models of rats: comparison with captopril.
Aono J; Koga T; Yamazaki T; Shiraki Y; Sakai K
Arch Int Pharmacodyn Ther; 1988; 292():203-22. PubMed ID: 3293542
[TBL] [Abstract][Full Text] [Related]
6. Antihypertensive effects of CI-907 (indolapril): a novel nonsulfhydryl angiotensin converting enzyme inhibitor.
Ryan MJ; Boucher DM; Cohen DM; Essenburg AD; Major TC; Mertz TE; Olszewski BJ; Randolph AE; Singer RM; Kaplan HR
J Pharmacol Exp Ther; 1984 Feb; 228(2):312-8. PubMed ID: 6319675
[TBL] [Abstract][Full Text] [Related]
7. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.
Gross DM; Sweet CS; Ulm EH; Backlund EP; Morris AA; Weitz D; Bohn DL; Wenger HC; Vassil TC; Stone CA
J Pharmacol Exp Ther; 1981 Mar; 216(3):552-7. PubMed ID: 6259322
[TBL] [Abstract][Full Text] [Related]
8. Preferential biliary elimination of FPL 63547, a novel inhibitor of angiotensin-converting enzyme, in the rat.
Carr RD; Cooper AE; Hutchinson R; Mann J; O'Connor SE; Robinson DH; Wells E
Br J Pharmacol; 1990 May; 100(1):90-4. PubMed ID: 2164864
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic, metabolic, and toxicologic profile of spirapril (SCH 33844), a new angiotensin converting inhibitor.
Sybertz EJ; Watkins RW; Ahn HS; Baum T; La Rocca P; Patrick J; Leitz F
J Cardiovasc Pharmacol; 1987; 10 Suppl 7():S105-8. PubMed ID: 2485040
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of angiotensin I-converting enzyme with S 9490: biochemical effects, interspecies differences, and role of sodium diet in hemodynamic effects.
Laubie M; Schiavi P; Vincent M; Schmitt H
J Cardiovasc Pharmacol; 1984; 6(6):1076-82. PubMed ID: 6084763
[TBL] [Abstract][Full Text] [Related]
11. Relationship between angiotensin I blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats.
Sweet CS; Arbegast PT; Gaul SL; Blaine EH; Gross DM
Eur J Pharmacol; 1981 Dec; 76(2-3):167-76. PubMed ID: 6174351
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive properties of a new long-acting angiotensin converting enzyme inhibitor in renin-dependent and independent hypertensive models.
Nagata S; Takeyama K; Fukuya F; Nagai R; Hosoki K; Nishimura K; Deguchi T; Karasawa T
Arzneimittelforschung; 1995 Aug; 45(8):853-8. PubMed ID: 7575746
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the actions of the angiotensin-converting enzyme inhibitors enalapril and S-9490-3 in sodium-deplete and sodium-replete spontaneously hypertensive rats.
DiNicolantonio R; Doyle AE
J Cardiovasc Pharmacol; 1985; 7(5):937-42. PubMed ID: 2413304
[TBL] [Abstract][Full Text] [Related]
14. Attenuation of pressor responses to intracerebroventricular angiotensin I by angiotensin converting enzyme inhibitors and their effects on systemic blood pressure in conscious rats.
Baum T; Becker FT; Sybertz EJ
Life Sci; 1983 Mar; 32(12):1297-303. PubMed ID: 6300578
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive activity of alacepril, an orally active angiotensin converting enzyme inhibitor, in renal hypertensive rats and dogs.
Takeyama K; Minato H; Fukuya F; Kawahara S; Hosoki K; Kadokawa T
Arzneimittelforschung; 1985; 35(10):1502-7. PubMed ID: 3000389
[TBL] [Abstract][Full Text] [Related]
16. A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor.
Waterfall JF
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):139S-150S. PubMed ID: 2527528
[TBL] [Abstract][Full Text] [Related]
17. Antihypertensive, hemodynamic and autonomic profile of a new angiotensin converting enzyme inhibitor, SCH 33844 (spirapril).
Baum T; Watkins RW; Sybertz EJ; Ahn HS; Nelson S; Coleman W; Tedesco R; Pula KK; Rivelli M; Sabin C
Arch Int Pharmacodyn Ther; 1987 Apr; 286(2):230-45. PubMed ID: 2884941
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme inhibitory activity of SCH 31846, a new non-sulfhydryl inhibitor.
Sybertz EJ; Baum T; Ahn HS; Nelson S; Eynon E; Desiderio DM; Pula K; Becker F; Sabin C; Moran R; Vander Vliet G; Kastner B; Smith E
J Cardiovasc Pharmacol; 1983; 5(4):643-54. PubMed ID: 6193364
[TBL] [Abstract][Full Text] [Related]
19. Biological properties of the angiotensin-converting enzyme inhibitor cilazapril.
Natoff IL; Nixon JS; Francis RJ; Klevans LR; Brewster M; Budd J; Patel AT; Wenger J; Worth E
J Cardiovasc Pharmacol; 1985; 7(3):569-80. PubMed ID: 2410692
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of angiotensin converting enzyme by CV-3317, a non-sulfhydryl compound.
Inada Y; Terashita Z; Imura Y; Tanabe M; Nishikawa K; Kikuchi S
Jpn J Pharmacol; 1986 Sep; 42(1):99-108. PubMed ID: 3025487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
